Tumefactive demyelination presenting during bevacizumab treatment.

ABSTRACT: We report the emergence of tumefactive demyelination during treatment with intravitreal bevacizumab (Avastin). This is of particular significance given that bevacizumab is currently being assessed as a potential treatment option for neuromyelitis optica, another demyelinating condition.

SUBMITTER: Rice CM 

PROVIDER: S-EPMC4691864 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature